• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

非酒精性脂肪性肝炎与肠道微生物群：对新疗法的启示

NASH and the Gut Microbiome: Implications for New Therapies.

作者信息

Tsay Cynthia J, Lim Joseph K

机构信息

Department of Internal Medicine Yale University New Haven CT.

Yale Liver Center and Section of Digestive Diseases Yale University New Haven CT.

出版信息

Clin Liver Dis (Hoboken). 2022 Jan 28;19(3):97-100. doi: 10.1002/cld.1170. eCollection 2022 Mar.

DOI:10.1002/cld.1170
PMID:35355843
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8958237/
Abstract

Content available: Author Audio Recording.

摘要

内容提供

作者音频记录。

相似文献

1
NASH and the Gut Microbiome: Implications for New Therapies.非酒精性脂肪性肝炎与肠道微生物群：对新疗法的启示
Clin Liver Dis (Hoboken). 2022 Jan 28;19(3):97-100. doi: 10.1002/cld.1170. eCollection 2022 Mar.
2
Modeling dysbiosis of human NASH in mice: Loss of gut microbiome diversity and overgrowth of Erysipelotrichales.在小鼠中模拟人类 NASH 的肠道菌群失调：肠道微生物多样性丧失和红螺菌目过度生长。
PLoS One. 2021 Jan 4;16(1):e0244763. doi: 10.1371/journal.pone.0244763. eCollection 2021.
3
Diet and gut microbiome in fatty liver and its associated liver cancer.饮食与肠道微生物群在脂肪肝及其相关肝癌中的作用。
J Gastroenterol Hepatol. 2022 Jan;37(1):7-14. doi: 10.1111/jgh.15713. Epub 2021 Nov 3.
4
Non-alcoholic fatty liver and the gut microbiota.非酒精性脂肪肝与肠道微生物群
Mol Metab. 2016 Jun 14;5(9):782-94. doi: 10.1016/j.molmet.2016.06.003. eCollection 2016 Sep.
5
Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake: A prospective pilot study.非酒精性脂肪性肝炎（NASH）瘦患者的肠道微生物群组成与肝损伤相关，且独立于热量摄入：一项前瞻性试点研究。
Nutr Metab Cardiovasc Dis. 2018 Apr;28(4):369-384. doi: 10.1016/j.numecd.2017.10.014. Epub 2017 Oct 26.
6
Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis.肠道微生物群对非酒精性脂肪性肝炎发生发展的影响。
Eur J Nutr. 2018 Apr;57(3):861-876. doi: 10.1007/s00394-017-1524-x. Epub 2017 Sep 5.
7
Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.了解肠道微生物组和微生物代谢物在非酒精性脂肪性肝病中的作用：当前的证据和观点。
Biomolecules. 2021 Dec 31;12(1):56. doi: 10.3390/biom12010056.
8
Gut microbiome and nonalcoholic fatty liver diseases.肠道微生物群与非酒精性脂肪性肝病
Pediatr Res. 2015 Jan;77(1-2):245-51. doi: 10.1038/pr.2014.157. Epub 2014 Oct 13.
9
Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications.综述文章：肠道微生物组在非酒精性脂肪性肝病进展中的新作用及其潜在的治疗意义。
Aliment Pharmacol Ther. 2019 Jul;50(2):144-158. doi: 10.1111/apt.15314. Epub 2019 May 31.
10
Epidemiological and Genetic Aspects of NAFLD and NASH in Mexico.墨西哥非酒精性脂肪性肝病和非酒精性脂肪性肝炎的流行病学及遗传学方面
Clin Liver Dis (Hoboken). 2022 Mar 10;19(2):68-72. doi: 10.1002/cld.1167. eCollection 2022 Feb.

引用本文的文献

1
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): the interplay of gut microbiome, insulin resistance, and diabetes.代谢功能障碍相关脂肪性肝病（MASLD）：肠道微生物群、胰岛素抵抗和糖尿病之间的相互作用
Front Med (Lausanne). 2025 Aug 14;12:1618275. doi: 10.3389/fmed.2025.1618275. eCollection 2025.
2
Ruminococcus gnavus in the gut: driver, contributor, or innocent bystander in steatotic liver disease?肠道中的迟缓瘤胃球菌：脂肪性肝病的驱动因素、促成因素还是无辜旁观者？
FEBS J. 2025 Mar;292(6):1252-1264. doi: 10.1111/febs.17327. Epub 2024 Nov 26.
3
A Scoping Review on Hepatoprotective Mechanism of Herbal Preparations through Gut Microbiota Modulation.通过调节肠道菌群对草药制剂肝脏保护机制的范围综述
Curr Issues Mol Biol. 2024 Oct 16;46(10):11460-11502. doi: 10.3390/cimb46100682.
4
Emerging Therapies for Non-Alcoholic Steatohepatitis (NASH): A Comprehensive Review of Pharmacological and Non-Pharmacological Approaches.非酒精性脂肪性肝炎（NASH）的新兴疗法：药理学和非药理学方法的全面综述
Cureus. 2024 Sep 10;16(9):e69129. doi: 10.7759/cureus.69129. eCollection 2024 Sep.
5
Development of non-alcoholic steatohepatitis is associated with gut microbiota but not with oxysterol enzymes CH25H, EBI2, or CYP7B1 in mice.非酒精性脂肪性肝炎的发生与肠道微生物群有关，但与小鼠中的胆甾醇 25-羟化酶、EBI2 或 CYP7B1 等氧化固醇酶无关。
BMC Microbiol. 2024 Feb 28;24(1):69. doi: 10.1186/s12866-024-03195-7.
6
The Role of in Liver Diseases: A Systematic Review of Next-Generation Sequencing Studies.[具体内容]在肝脏疾病中的作用：下一代测序研究的系统评价
Microorganisms. 2023 Dec 17;11(12):2999. doi: 10.3390/microorganisms11122999.
7
Gut Microbiome in the Progression of NAFLD, NASH and Cirrhosis, and Its Connection with Biotics: A Bibliometric Study Using Dimensions Scientific Research Database.非酒精性脂肪性肝病、非酒精性脂肪性肝炎和肝硬化进展中的肠道微生物群及其与生物制剂的联系：一项使用Dimensions科学研究数据库的文献计量学研究
Biology (Basel). 2023 Apr 27;12(5):662. doi: 10.3390/biology12050662.
8
Excessive gluconeogenesis causes the hepatic insulin resistance paradox and its sequelae.过量的糖异生会导致肝脏胰岛素抵抗悖论及其后遗症。
Heliyon. 2022 Dec 15;8(12):e12294. doi: 10.1016/j.heliyon.2022.e12294. eCollection 2022 Dec.
9
Clearing Steatosis Prior to Liver Surgery for Colorectal Metastasis: A Narrative Review and Case Illustration.结直肠转移肝切除术前肝脂肪变性的处理：叙述性综述及病例说明。
Nutrients. 2022 Dec 15;14(24):5340. doi: 10.3390/nu14245340.

本文引用的文献

1
An update on the role of the microbiome in non-alcoholic fatty liver disease pathogenesis, diagnosis, and treatment.微生物群在非酒精性脂肪性肝病发病机制、诊断和治疗中的作用的最新进展。
Curr Treat Options Gastroenterol. 2020 Jun;18(2):270-280. doi: 10.1007/s11938-020-00290-2. Epub 2020 May 2.
2
The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies.益生菌在非酒精性脂肪性肝病中的作用：治疗策略的新视角。
Nutrients. 2019 Nov 4;11(11):2642. doi: 10.3390/nu11112642.
3
Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications.综述文章：肠道微生物组在非酒精性脂肪性肝病进展中的新作用及其潜在的治疗意义。
Aliment Pharmacol Ther. 2019 Jul;50(2):144-158. doi: 10.1111/apt.15314. Epub 2019 May 31.
4
Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.肠道微生物群：非酒精性脂肪性肝病的新治疗靶点。
Expert Rev Gastroenterol Hepatol. 2019 Mar;13(3):193-204. doi: 10.1080/17474124.2019.1569513. Epub 2019 Jan 25.
5
The Intestinal Microbiome, Plasma Metabolome, and Liver Transcriptome: A Conspiracy Driving Hepatic Steatosis.肠道微生物组、血浆代谢组和肝脏转录组：驱动肝脂肪变性的一个“阴谋”
Hepatology. 2019 Aug;70(2):741-744. doi: 10.1002/hep.30577. Epub 2019 Apr 11.
6
The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD).肠道微生物组与非酒精性脂肪性肝病（NAFLD）之间的联系。
Cell Mol Life Sci. 2019 Apr;76(8):1541-1558. doi: 10.1007/s00018-019-03011-w. Epub 2019 Jan 25.
7
The role of the microbiome in NAFLD and NASH.微生物组在非酒精性脂肪性肝病和非酒精性脂肪性肝炎中的作用。
EMBO Mol Med. 2019 Feb;11(2). doi: 10.15252/emmm.201809302.
8
Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function.肠道微生物组在非酒精性脂肪性肝病中的新作用：从组成到功能。
Clin Gastroenterol Hepatol. 2019 Jan;17(2):296-306. doi: 10.1016/j.cgh.2018.08.065. Epub 2018 Sep 7.
9
Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy.肠道微生物群与非酒精性脂肪性肝病：机制与治疗的新视角。
Nutrients. 2017 Oct 16;9(10):1124. doi: 10.3390/nu9101124.
10
Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition.代谢综合征患者接受瘦供体粪便后胰岛素敏感性改善是由基线肠道微生物组成决定的。
Cell Metab. 2017 Oct 3;26(4):611-619.e6. doi: 10.1016/j.cmet.2017.09.008.